Oncology Corporate Profile
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVACA, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Prostvac® / rilimogene||immunotherapy||Prostate cancer||III||Bristol-Myers Squibb|
|CV301 (+ nivolumab)||immunotherapy||Non Small Cell Lung Cancer (NSCLC)||II|
|Prostvac® / rilimogene (+ ipilimumab)||immunotherapy||Prostate cancer||II||Bristol-Myers Squibb|
|MVA-BN Brachyury||immunotherapy||Various cancer types||I|
View additional information on product candidates here »